Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Influence of a 23S ribosomal RNA mutation in Helicobacter pylori strains on the in vitro synergistic effect of clarithromycin and amoxicillin.

Sakinc T, Baars B, Wüppenhorst N, Kist M, Huebner J, Opferkuch W.

BMC Res Notes. 2012 Oct 30;5:603. doi: 10.1186/1756-0500-5-603.

2.

Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome.

Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W.

Am J Gastroenterol. 1998 Mar;93(3):386-9.

PMID:
9517645
3.

Partial characterization of a cell proliferation-inhibiting protein produced by Helicobacter pylori.

Knipp U, Birkholz S, Kaup W, Opferkuch W.

Infect Immun. 1996 Sep;64(9):3491-6.

4.

The influence of sulbactam on the in vitro activity of mezlocillin, piperacillin and cefotaxime.

Bauernfeind A, Grimm H, Klietmann W, Opferkuch W, Werner H.

Int J Antimicrob Agents. 1996 Apr;6 Suppl:S15-26.

PMID:
18611715
5.

Cure of Helicobacter pylori infection: role of duration of treatment with omeprazole and amoxicillin.

Adamek RJ, Opferkuch W, Pfaffenbach B, Wegener M.

Am J Gastroenterol. 1996 Jan;91(1):98-100.

PMID:
8561153
6.

[The epidemiology of Helicobacter pylori].

Opferkuch W.

Bildgebung. 1995 Apr;62 Suppl 1:57-8. German. No abstract available.

PMID:
7670307
7.

[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection].

Adamek RJ, Szymanski C, Pfaffenbach B, Opferkuch W, Ricken D, Wegener M.

Dtsch Med Wochenschr. 1995 Mar 17;120(11):358-60. German.

PMID:
7889816
9.

Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection.

Adamek RJ, Opferkuch W, Wegener M.

Am J Gastroenterol. 1995 Jan;90(1):168-9. No abstract available.

PMID:
7801936
10.

Effect of Helicobacter pylori on dbc-AMP stimulated acid secretion by human parietal cells.

Jablonowski H, Hengels KJ, Krämer N, Geis G, Opferkuch W, Strohmeyer G.

Hepatogastroenterology. 1994 Dec;41(6):546-8.

PMID:
7721241
11.

[The modified 13C-urea breath test in the diagnosis of Helicobacter pylori colonization of the gastric mucosa].

Adamek RJ, Freitag M, Labenz J, Opferkuch W, Rühl GH, Aygen S, Hennemann O, Wegener M.

Dtsch Med Wochenschr. 1994 Nov 18;119(46):1569-72. German.

PMID:
7956797
12.

Intravenous omeprazole/amoxicillin and omeprazole pretreatment in Helicobacter pylori-positive acute peptide ulcer bleeding. A pilot study.

Adamek RJ, Freitag M, Opferkuch W, Rühl GH, Wegener M.

Scand J Gastroenterol. 1994 Oct;29(10):880-3.

PMID:
7839093
13.

Short-term omeprazole oral/amoxicillin intravenous therapy for Helicobacter pylori eradication: a lack of therapeutic effect.

Adamek RJ, Opferkuch W, Wegener M.

Am J Gastroenterol. 1994 Sep;89(9):1602-3. No abstract available.

PMID:
8079960
14.

Expression of capsular polysaccharide determines serum resistance in Escherichia coli K92.

Suerbaum S, Friedrich S, Leying H, Opferkuch W.

Zentralbl Bakteriol. 1994 Aug;281(2):146-57.

PMID:
7858342
15.

Fumarate reductase of Helicobacter pylori--an immunogenic protein.

Birkholz S, Knipp U, Lemma E, Kröger A, Opferkuch W.

J Med Microbiol. 1994 Jul;41(1):56-62.

PMID:
8006945
16.

Effects of Helicobacter pylori on histamine and carbachol stimulated acid secretion by human parietal cells.

Jablonowski H, Hengels KJ, Kraemer N, Geis G, Opferkuch W, Strohmeyer G.

Gut. 1994 Jun;35(6):755-7.

17.

[Omeprazole modified antibiotic therapy of Helicobacter pylori infection: can clarithromycin be replaced by roxithromycin?].

Labenz J, Wegener M, Adamek RJ, Opferkuch W, Rühl GH, Börsch G.

Leber Magen Darm. 1994 Mar;24(2):73-5. German.

PMID:
8196468
18.

Suppression of human mononuclear cell response by Helicobacter pylori: effects on isolated monocytes and lymphocytes.

Knipp U, Birkholz S, Kaup W, Mahnke K, Opferkuch W.

FEMS Immunol Med Microbiol. 1994 Feb;8(2):157-66.

PMID:
7909699
19.

Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy.

Adamek RJ, Wegener M, Labenz J, Freitag M, Opferkuch W, Rühl GH.

Am J Gastroenterol. 1994 Jan;89(1):39-42.

PMID:
8273795
20.
21.

Ultrastructure and biochemical studies of the flagellar sheath of Helicobacter pylori.

Geis G, Suerbaum S, Forsthoff B, Leying H, Opferkuch W.

J Med Microbiol. 1993 May;38(5):371-7.

PMID:
8487294
22.

Successful Helicobacter pylori eradication: a systemic effect of antibiotics?

Adamek RJ, Wegener M, Opferkuch W, Rühl GH.

Am J Gastroenterol. 1993 May;88(5):792-3. No abstract available.

PMID:
8480762
23.

Immune suppressive effects of Helicobacter pylori on human peripheral blood mononuclear cells.

Knipp U, Birkholz S, Kaup W, Opferkuch W.

Med Microbiol Immunol. 1993 May;182(2):63-76.

PMID:
8332102
24.
25.

[Modified combined omeprazole/amoxicillin therapy for Helicobacter pylori eradication: a pilot study].

Adamek RJ, Wegener M, Birkholz S, Opferkuch W, Rühl GH, Ricken D.

Leber Magen Darm. 1992 Nov;22(6):222-4. German.

PMID:
1479866
26.

[Helicobacter pylori: the local IgA response of the gastric mucosa].

Opferkuch W, Birkholz S.

Dtsch Med Wochenschr. 1992 Oct 23;117(43):1661. German. No abstract available.

PMID:
1425270
27.

Biochemical studies of Helicobacter mustelae fatty acid composition and flagella.

Suerbaum S, Geis G, Josenhans C, Opferkuch W.

Infect Immun. 1992 Apr;60(4):1695-8.

28.

[The effect of sulbactam on the in vitro activity of mezlocillin, piperacillin and cefotaxime].

Bauernfeind A, Grimm H, Klietmann W, Opferkuch W, Werner H.

Arzneimittelforschung. 1991 Aug;41(8):831-8. German.

PMID:
1781806
29.

Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori.

Suerbaum S, Leying H, Klemm K, Opferkuch W.

Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):92-3. No abstract available.

PMID:
1864281
30.

Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins.

Gehrlein M, Leying H, Cullmann W, Wendt S, Opferkuch W.

Chemotherapy. 1991;37(6):405-12.

PMID:
1760939
31.

Intermediate filaments vimentin and desmin share epitopes with M 1 protein of group A streptococci.

Birkholz S, Goroncy-Bermes P, Schönermark M, Hänsch GM, Opferkuch W.

Zentralbl Bakteriol. 1990 Nov;274(2):183-94.

PMID:
1707626
32.
33.

Unusual fatty acid substitution in lipids and lipopolysaccharides of Helicobacter pylori.

Geis G, Leying H, Suerbaum S, Opferkuch W.

J Clin Microbiol. 1990 May;28(5):930-2.

34.

Influence of beta-lactam antibiotics on serum resistance of K1-positive blood culture isolates of Escherichia coli.

Suerbaum S, Leying H, Meyer B, Opferkuch W.

Antimicrob Agents Chemother. 1990 Apr;34(4):628-31.

35.
36.

[Antibiotics for Campylobacter pylori colonization of the stomach].

Schmidt G, Opferkuch W, Rühl G, Haase G.

Dtsch Med Wochenschr. 1989 Nov 17;114(46):1812-3. German. No abstract available.

PMID:
2583013
37.

[A comment on the contribution by H. Rosin: "Beta-lactam antibiotics"].

Cullmann W, Opferkuch W.

Internist (Berl). 1989 Sep;30(9):628-9. German. No abstract available.

PMID:
2807787
38.

A third mechanism of serum resistance in Escherichia coli.

Kubens BS, Nikolai S, Opferkuch W.

Zentralbl Bakteriol. 1989 Jul;271(2):222-30.

PMID:
2528357
39.

[Campylobacter pylori: clinical correlations and prospective comparative studies of various diagnostic techniques].

Börsch G, Mai U, Reitemeyer E, Leverkus F, Opferkuch W.

Immun Infekt. 1989 Jun;17(3):83-90. German.

PMID:
2759652
40.

[Serodiagnosis of Campylobacter pylori].

Rolke J, Börsch G, Geis G, Mai U, Opferkuch W.

Immun Infekt. 1989 Jun;17(3):78-82. German.

PMID:
2759651
41.

[Campylobacter pylori].

Opferkuch W.

Immun Infekt. 1989 Jun;17(3):77. German. No abstract available.

PMID:
2759650
42.

Ultrastructure and chemical analysis of Campylobacter pylori flagella.

Geis G, Leying H, Suerbaum S, Mai U, Opferkuch W.

J Clin Microbiol. 1989 Mar;27(3):436-41.

43.

[Infections of the lower respiratory tract].

Opferkuch W.

Immun Infekt. 1989 Feb;17(1):3. German. No abstract available.

PMID:
2925222
44.

Studies on serum resistance in Escherichia coli.

Kubens BS, Opferkuch W.

Zentralbl Bakteriol Mikrobiol Hyg A. 1988 Nov;270(1-2):52-65.

PMID:
3146846
45.

Two different mechanisms of serum resistance in Escherichia coli.

Kubens BS, Wettstein M, Opferkuch W.

Microb Pathog. 1988 Nov;5(5):371-9.

PMID:
3070267
46.
47.

Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin.

Mayer M, Tophof C, Opferkuch W.

Infection. 1988 Jul-Aug;16(4):225-8.

PMID:
3182087
48.

[Microbiology of Campylobacter pylori].

Mai U, Opferkuch W.

Leber Magen Darm. 1988 Feb;18(1):31-7. Review. German.

PMID:
3280931
50.

Sulbactam and clavulanic acid: studies of enzyme kinetics and synergy with ampicillin and mezlocillin.

Cullmann W, Stieglitz M, Opferkuch W.

Drugs. 1988;35 Suppl 7:71-6. No abstract available.

PMID:
3220009

Supplemental Content

Loading ...
Support Center